News

BUNAVAIL is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. BDSI

The 220,000-square-foot expansion was announced by Huntsman at the annual fundraising gala last November. With Architectural Nexus as the architect and Jacobsen Construction as the builder, the addition

Earlier in 2014, the US Food and Drug Administration (FDA) had approved Pradaxa to treat patients with DVT and PE. The company said that almost one in three

The expansion is anticipated to be fully operational end of the first quarter of 2015. The new 2,000 L single-use bioreactor will supplement two existing 1,000 L single-use

The submitted pre-IND package provides the US FDA with information on the company’s REV-002, as well as a clinical trial plan for a proposed US clinical trial. The

The payment settles charges brought by 45 state attorneys general, while California’s portion of the settlement is around $7.1m. The settlement prohibits the UK drug-maker from providing incentive

The final closing of the transaction is expected to take place on or before 07 July 2014. The acquisition is a significant milestone for GelStat and is expected

Recently, the US Adopted Names (USAN) Council has adopted necuparanib as the unique non-proprietary name for M402. Necuparanib, a heparan sulfate mimetic, is a novel oncology drug candidate

The patent is expected to be issued during 2014 and will have a 2029 expiry date. RHB-104 is a proprietary antibiotic combination oral capsule formulation for the treatment